


Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

Note: The screening technique should be performed with a consistent technique and process.

INITIAL ASSESSMENT

RISK FACTORS

SCREENING



¹ Diagnosis of cirrhosis based on imaging and pathology

² These patients require management by an experienced clinician

³ AFP as a sole screening marker is inadequate

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.

SUGGESTED READINGS

- American Association for the Study of Liver Diseases and the Infectious Diseases Society of America. (2020). HCV guidance: Recommendations for testing, managing, and treating hepatitis C. Retrieved from <https://www.hcvguidelines.org/>
- Bruix, J., & Sherman, M. (2011). Management of hepatocellular carcinoma: An update. *Hepatology*, 53(3), 1020-1022. <https://doi.org/10.1002/hep.24199>
- Centers for Disease Control and Prevention. (2023). Testing recommendations for hepatitis C virus infection. Retrieved from <https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm>
- European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer. (2012). EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. *Journal of Hepatology*, 56(4), 908-943. <https://doi.org/10.1016/j.jhep.2011.12.001>
- Lok, A. S., Seeff, L. B., Morgan, T. R., Di Bisceglie, A. M., Sterling, R. K., Curto, T. M., . . . HALT-C Trial Group. (2009). Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. *Gastroenterology*, 136(1), 138-148. <https://doi.org/10.1053/j.gastro.2008.09.014>
- Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973). Transection of the oesophagus for bleeding oesophageal varices. *British Journal of Surgery*, 60(8), 646-649. <https://doi.org/10.1002/bjs.1800600817>
- Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., . . . Newsome, P. N. (2023). A multisociety Delphi consensus statement on new fatty liver disease nomenclature. *Hepatology*, 78(6), 1966-1986. <https://doi.org/10.1097/HEP.0000000000000520>
- Smith, B. D., Morgan, R. L., Beckett, G. A., Falck-Ytter, Y., Holtzman, D., Teo, C. G., . . . Ward, J. W. (2012). Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. *Morbidity and Mortality Weekly Report: Recommendations and Reports*, 61(4), 1-32. Retrieved from <http://www.jstor.org/stable/24832523>
- Terrault, N. A., Lok, A. S. F., McMahon, B. J., Chang, K. M., Hwang, J. P., Jonas, M. M., . . . Wong, J. B. (2018). Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*, 67(4), 1560-1599. <https://doi.org/10.1002/hep.29800>
- US Preventive Services Task Force. (2020). Screening for hepatitis B virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. *The Journal of the American Medical Association*, 324(23), 2415-2422. <https://doi.org/10.1001/jama.2020.22980>
- US Preventive Services Task Force. (2020). Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force recommendation statement. *The Journal of the American Medical Association*, 323(10), 970-975. <https://doi.org/10.1001/jama.2020.1123>

Disclaimer: *This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson's specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient's care.*

DEVELOPMENT CREDITS

This screening algorithm is based on majority expert opinion of the Liver Screening workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

Core Development Team Leads

Therese Bevers, MD (Cancer Prevention)
Marta Davila, MD (Gastroenterology Hepatology and Nutrition)
Manal Hassan, MD, MPH, PhD (Epidemiology)
Jessica Hwang, MD, MPH (General Internal Medicine)
Ahmed Kaseb, MD (GI Medical Oncology)
Harmeet Kaur, MD (Abdominal Imaging)
Evelyne Loyer, MD (Abdominal Imaging)

Workgroup Members

Heather Alexander, PgDip, BA (Community Alliances)
Tharakeswara Bathala, MD (Abdominal Imaging)
Deepak Bedi, MD (Abdominal Imaging)
Joyce Dains, DrPH, APRN, FNP-BC (Nursing)
Wendy Garcia, BS♦
Ernest Hawk, MD, MPH (Cancer Prevention)
Ethan Miller, MD (Gastroenterology Hepatology and Nutrition)
Ana Nelson, APRN, FNP-BC (Cancer Prevention)
Harrys Torres, MD (Infectious Diseases)
Jean-Nicolas Vauthey, MD (Surgical Oncology)
Eduardo Vilar-Sanchez, MD, PhD (Cancer Prevention)
Hannah Warr, MSN, RN, CPHON♦

♦ Clinical Effectiveness Development Team